Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Bone|May 26, 2009
Efficacy and safety of 2 g/day of strontium ranelate in Asian women with postmenopausal osteoporosisJian-Min Liu, Annie Wai-Chee Kung, Chan Siew Pheng, et al.
Acta Pharmacologica Sinica|February 4, 2012
Association of ALOX15 gene polymorphisms with obesity-related phenotypes in Chinese nuclear families with male offspringYao-hua Ke, Wen-jin Xiao, Jin-wei He, et al.
Medicine|August 5, 2018
Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in ChinaEr-Yuan Liao, Zhen-Lin Zhang, Wei-Bo Xia, et al.
Acta Pharmacologica Sinica|June 9, 2015
The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year dataJie-mei Gu, Li Wang, Hua Lin, et al.
Menopause (New York, N.Y.)|September 13, 2012
Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosisMei Li, Zhen-Lin Zhang, Er-yuan Liao, et al.
BMC Musculoskeletal Disorders|July 5, 2018
Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D3 combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisalEr-Yuan Liao, Zhen-Lin Zhang, Wei-Bo Xia, et al.
Plos One|December 17, 2011
Association between low density lipoprotein receptor-related protein 2 gene polymorphisms and bone mineral density variation in Chinese populationChun Wang, Yi-Ming Hu, Jin-Wei He, et al.
Human Molecular Genetics|December 16, 2011
Post-genome wide association studies and functional analyses identify association of MPP7 gene variants with site-specific bone mineral densitySu-Mei Xiao, Annie Wai Chee Kung, Yi Gao, et al.
Acta Pharmacologica Sinica|July 27, 2022
A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture riskHao Zhang, Jie-Mei Gu, Ai-Jun Chao, et al.
American Journal of Human Genetics|January 26, 2010
Association of JAG1 with bone mineral density and osteoporotic fractures: a genome-wide association study and follow-up replication studiesAnnie W C Kung, Su-Mei Xiao, Stacey Cherny, et al.
Pageof 13